VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PBYI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PBYIPuma Biotechnology, Inc.
$7.22$367M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PBYI logo

Puma Biotechnology, Inc.

PBYI
NASDAQ · Oncology Biotech
$7.22
At close - Nov 18, 4:00 PM EST - USD
Market Cap$367M
P/E16.1x
52W High$11.50
Volume454.06K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Erratic Revenue Path Obscures Deleveraging and Margin Resilience

Puma Biotechnology's investment case is defined by a stark contrast between its structurally high gross margins, averaging ~75%, and its volatile revenue trajectory, which has swung from a 32.4% decline to a 27.7% surge in recent quarters.

GrowthMixed
ProfitabilityModerate
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

PBYI price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

11/12 Beats

EPS beat 11 of last 12 quarters

02

Valuation risk

-39% Peers

P/E is 39% below peer median

03

Market leadership

RS 65 · Avg

Average momentum (RS Rating: 65)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PBYI+25.13%
S&P 500 (^GSPC)+6.88%
1-Year Return
PBYI+42.69%
S&P 500 (^GSPC)+10.62%
3-Year Return
PBYI+85.60%
S&P 500 (^GSPC)+60.88%
5-Year Return
PBYI+114.24%
S&P 500 (^GSPC)+64.19%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
16.1x
Forward P/E
19.0x
EV/EBITDA80th %ile
10.8x
FCF YieldCash Flow
3.9%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
16.1x
9.8x
75th· Fair
EV/EBITDA
10.8x
6.2x
80th· High
Price/FCF
25.4x
7.2x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$228M-0.9% YoY
Net income FY25
$31M+2.8% YoY
Free cash flow FY25
$42M+7.4% YoY
Operating margin FY25
16.3%+2.9 pts YoY
ROIC (FY25)24.7%
Avg ROIC 5Y24.1%
ROE (TTM)24%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate11/12 (92%)
Revenue Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$0.15+66.7%
vs $0.09
$54M-5.9%
vs $58M
Q3 2026
Aug 6, 2026
$0.19+375.0%
vs $0.04
$57M+6.6%
vs $53M
Q2 2026
May 7, 2026
-$0.04+69.2%
vs -$0.13
$45M+6.7%
vs $42M
Q1 2026
Feb 26, 2026
$0.29+20.8%
vs $0.24
$60M-12.7%
vs $69M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 6, 2026
Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript

Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript

MarketBeat·Nov 6, 2026
Puma Biotechnology Q3 Earnings Call Highlights

Puma Biotechnology NASDAQ: PBYI reported third-quarter 2026 revenue of $55.1 million and raised its full-year net income forecast, even as it lowered its outlook for royalties and narrowed its sales guidance for breast cancer drug NERLYNX.

Business Wire·Nov 5, 2026
Puma Biotechnology Reports Third Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its third quarter earnings on Nov. 5 and followed with a conference call to provide a corporate update.

Business Wire·Nov 4, 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported that it granted inducement awards in October 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Filtered for Puma Biotechnology, Inc.More Headlines
04

Compare before deciding

Benchmark PBYI against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Puma Biotechnology, Inc. (PBYI)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PBYI logoPBYIPuma Biotechnology, Inc.Current
$7.22$367.49M16.06-0.91%10.3%24.04%—
RCUS logoRCUSArcus Biosciences, Inc.
$15.76$1.98B-4.51-4.26%-445%-90.04%—
TGTX logoTGTXTG Therapeutics, Inc.
$66.12$10.12B97.2187.32%11.81%17.62%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.23$5B-47.44114.51%-9.17%——
ACAD logoACADACADIA Pharmaceuticals Inc.
$17.83$3.05B8.6411.87%30.13%28.03%—
EXEL logoEXELExelixis, Inc.
$68.29$17.17B19.736.98%35.45%45.54%—

Compare PBYI vs Peers

Puma Biotechnology, Inc. (PBYI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RCUS

Most directly comparable listed peer for PBYI.

Scale Benchmark

vs AZN

Larger-name benchmark to compare PBYI against a more recognizable public peer.

Peer Set

Compare Top 5

vs RCUS, TGTX, PTCT, ACAD

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PBYI SEC Filings & Documents

Puma Biotechnology, Inc. (PBYI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jun 16, 2026·SEC

Material company update

May 7, 2026·SEC

10-K Annual Reports

4
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when PBYI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PBYI Frequently Asked Questions

Puma Biotechnology, Inc. (PBYI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Puma Biotechnology, Inc.'s revenue?

Puma Biotechnology, Inc. (PBYI) reported $231.9M in revenue over the trailing twelve months. Revenue was $228.4M in fiscal year 2025.

How fast is Puma Biotechnology, Inc. growing?

Puma Biotechnology, Inc. (PBYI) grew revenue by 9.4% over the trailing twelve months, compared with the twelve months before.

Is PBYI profitable?

Yes. Puma Biotechnology, Inc. (PBYI) earned $23.9M in net income over the trailing twelve months (a 10.3% net margin).

Dividend & Returns
What is PBYI's return on equity?

Puma Biotechnology, Inc. (PBYI) had a return on equity (ROE) of 24.0% over the trailing twelve months. That is well above the market's typical 10-15%.

What is Puma Biotechnology, Inc.'s free cash flow?

Puma Biotechnology, Inc. (PBYI) generated $14.5M in free cash flow over the trailing twelve months.

What if you invested $1,000 in PBYI back in 2007?

Total return calculator · dividends reinvested · 19+ years of data

See returns →